Journal of gastroenterology and hepatology · 2026
Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ouchi Keishi, Ninomiya Masashi, Tsuruoka Mio, Inoue Jun, Hiraoka Atsushi, Sato Kosuke, Doi Kotaro, Watanabe Kengo, Sasazaki Tomoya, Oikawa Takayoshi, Endo Kei, Abe Tamami, Fujita Masashi, Abe Kazumichi, Katsumi Tomohiro, Sato Wataru, Iino Chikara, Tanabe Nobukazu, Numao Hiroshi, Ohira Hiromasa, Kuroda Hidekatsu, Ueno Yoshiyuki, Masamune Atsushi
Аннотация
BACKGROUND AND AIM: The optimal treatment strategy for patients with intermediate-stage hepatocellular carcinoma beyond the up-to-seven criteria (Barcelona Clinic Liver Cancer B2) remains uncertain. Although transarterial chemoembolization has long been the standard of care, its efficacy is limited in this subgroup, and systemic therapies have recently been introduced. We aimed to explore treatment modalities associated with survival beyond that predicted by a previously validated prognostic model.
METHODS: We retrospectively analyzed 113 patients diagnosed with BCLC-B2 stage hepatocellular carcinoma between 2017 and 2024. Predicted survival was calculated using a previously established prognostic model, and treatment benefits were evaluated by comparing observed survival with predicted outcomes. Logistic and linear regression analyses were performed to identify factors associated with survival gain.
RESULTS: The median observed survival was 26.0 months, compared with a model-predicted survival of 24.7 months. Treatment with atezolizumab plus bevacizumab was significantly associated with survival exceeding model predictions (odds ratio: 3.77, p = 0.0065). Linear regression analysis confirmed that atezolizumab plus bevacizumab was independently associated with a greater survival benefit (β = 0.192, p = 0.0084). Subgroup analysis demonstrated that this association was particularly pronounced in patients with high tumor burden (tumor number plus size ≥ 11), whereas no significant associations were observed for lenvatinib, STRIDE, or cabozantinib.
CONCLUSIONS: Atezolizumab plus bevacizumab was associated with survival beyond that predicted by a prognostic model in patients with BCLC-B2 stage hepatocellular carcinoma, particularly those with high tumor burden. These findings should be considered exploratory and associative rather than evidence of a causal treatment effect.
METHODS: We retrospectively analyzed 113 patients diagnosed with BCLC-B2 stage hepatocellular carcinoma between 2017 and 2024. Predicted survival was calculated using a previously established prognostic model, and treatment benefits were evaluated by comparing observed survival with predicted outcomes. Logistic and linear regression analyses were performed to identify factors associated with survival gain.
RESULTS: The median observed survival was 26.0 months, compared with a model-predicted survival of 24.7 months. Treatment with atezolizumab plus bevacizumab was significantly associated with survival exceeding model predictions (odds ratio: 3.77, p = 0.0065). Linear regression analysis confirmed that atezolizumab plus bevacizumab was independently associated with a greater survival benefit (β = 0.192, p = 0.0084). Subgroup analysis demonstrated that this association was particularly pronounced in patients with high tumor burden (tumor number plus size ≥ 11), whereas no significant associations were observed for lenvatinib, STRIDE, or cabozantinib.
CONCLUSIONS: Atezolizumab plus bevacizumab was associated with survival beyond that predicted by a prognostic model in patients with BCLC-B2 stage hepatocellular carcinoma, particularly those with high tumor burden. These findings should be considered exploratory and associative rather than evidence of a causal treatment effect.